Daily Target 2X Long MRNA ETF (MRNX) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Daily Target 2X Long MRNA ETF (MRNX) operates in the Financial Services sector, specifically the Asset Management - Leveraged industry, with a market capitalization near $1.6M, listed on AMEX, carrying a beta of -2.89 to the broader market. The MRNX fund is designed to generate returns by taking a leveraged, bullish stance on the daily share price movements of Moderna, Inc. Led by James Atkinson, public since 2026-02-04.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for MRNX as of 2026-07-17; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.